Chapter 21 Further Reading — Oxytocin and Vasopressin

A note before the list. This is a chapter about a literature that says one thing in its primary sources and something quite different in its popular retellings. That makes source selection unusually consequential here. The tiers below are ordered by how much technical background they assume, not by how much you should trust them — everything listed is worth reading, and several entries are listed precisely because they disagree with each other.

A standing warning specific to this topic: search results for "oxytocin" are heavily contaminated by product marketing and by a decade of enthusiastic popular coverage that has not been updated. If a source published after roughly 2015 still describes oxytocin as the love or trust hormone without qualification, it is not tracking its own field.

Tier 1 — Orientation

For readers who want the shape of the story without the methodological machinery.

Reputable general-audience coverage of the replication crisis in psychology. Not oxytocin-specific, and that is the point. Understanding why small studies of small effects produce inflated published findings is the single most transferable thing in this chapter, and it lands better when you meet it outside the case you already have opinions about. Look for treatments that cover preregistration and multi-lab replication projects as responses, not just the problem as an indictment.

Science journalism that covered the oxytocin correction rather than the original finding. These exist and are worth seeking out specifically. A useful exercise: find a piece from roughly 2008–2012 enthusiastically reporting the trust findings, then find a piece from roughly 2015 onward reporting the replication difficulties, and read them consecutively. The contrast in tone is itself data about how science communication works.

Neurodiversity writing by autistic authors on the framing of autism research. Chapter 21 §21.7 states the position; it does not make the case at length, and it should not be the only place you encounter it. First-person accounts of what "treatment" framing means in practice, and of what autistic people actually want research to prioritize, will change how you read a clinical trial's outcome measures.

Basic obstetric patient information on oxytocin for labor. Because the ✅ half of this chapter is the half most readers know least about, and clear patient-facing material from a professional obstetric body will give you the real clinical picture in a few pages.

Tier 2 — Working knowledge

For readers comfortable with review articles and willing to sit with a methods section.

Critical reviews of the human oxytocin-and-trust literature. The most useful of these evaluate the evidence base as a whole rather than reporting individual studies, and address statistical power, publication bias, and effect-size inflation directly. This is where the ⚠️ → ❌ reasoning in §21.4 comes from, and reading the argument in full is more convincing than reading a summary of it.

The preregistered multi-site replication work on oxytocin and trust. Read the design first, before the result. Note what preregistration actually constrains — outcomes, analyses, exclusions — and ask yourself which of those degrees of freedom you would have used without noticing, had you run the original study.

Reviews of context-dependence in oxytocin's social effects. The literature reframing oxytocin around social salience, person-level moderators, and situational framing. This is the most intellectually interesting body of work in the chapter and the least covered in popular sources. Pay attention to how the authors handle the tension between "our reframing explains the inconsistent results" and "our reframing was tested with the same tools that produced the inconsistent results."

The intranasal delivery debate, read from both sides. There is a well-known and pointedly titled critique in the neuroendocrinology literature arguing that confident claims about intranasal oxytocin reaching the brain are unsupported, and there are substantive replies from researchers working on nasal delivery. Read at least one of each. This is the best available exercise in the book for practicing what it feels like to hold an unresolved technical controversy open rather than picking a side for comfort.

The large multisite autism trial and the meta-analyses around it. Read the primary trial report for the design, the population, and — critically — the prespecified primary outcome and how it was chosen. Then read a meta-analysis. Then ask what the field would have concluded had only the small early trials existed, which for several years is exactly the situation it was in.

Clinical reference material on desmopressin and on vasopressin in critical care. Chapter 29 covers desmopressin in full, so this is optional here, but a good clinical monograph will show you how much of a molecule's real profile lives in its warnings rather than its indications.

Tier 3 — Depth

For readers who want the primary literature and the historical record.

du Vigneaud's Nobel lecture (1955). Short, readable, and a genuine pleasure. It is a first-person account of establishing that a hormone is a molecule and nothing more, written by the person who did it, at the moment the field changed. It is also a useful antidote to the impression that peptide chemistry was ever easy.

The primary prairie vole literature. The comparative receptor-distribution studies and the subsequent causal manipulations. Read for the experimental design above all: notice how much work goes into the species comparison before any manipulation happens, and notice how carefully the original authors state their conclusions compared to how those conclusions were later reported.

The original human trust-game paper and the critical response literature, read as a pair. This is the fullest version of the §21.4 exercise. The original is a competent piece of work by the standards of its time, which is the uncomfortable and important thing about it.

The intergroup-conflict experimental literature on oxytocin. In-group favoritism, out-group defensiveness, and the associated work on competitive emotions and on person-level moderators such as attachment style. This is the empirical basis for §21.5 and for the ❌ on the nickname. Read the methods carefully — the paradigms are more clever and more specific than the summaries suggest, and the specificity is part of the finding.

Vasopressin receptor pharmacology and the V1a antagonist clinical program in autism. A serious, well-funded translational effort from receptor biology to large clinical trials that did not deliver on its primary endpoints. Following a program like this end to end is one of the most educational things available to a reader of this book, because it shows the whole arc — mechanism, hypothesis, investment, trial, result — for a case where the result was negative and almost nobody outside the field heard about it.

Methodological literature on oxytocin measurement. The extraction-versus-non-extraction assay problem. Dry, technical, and quietly devastating for any study that correlated circulating oxytocin with behavior.

If you only do one thing

Find the pointed critique of intranasal oxytocin delivery in the neuroendocrinology literature, read it, then find a substantive reply from researchers who work on nasal delivery and read that.

Two papers. An afternoon.

Do it because this chapter's most valuable transferable skill is not knowing what oxytocin does. It is being able to sit inside a genuine technical disagreement between competent people and not resolve it prematurely — to come out able to say "here is what each side is claiming, here is what evidence would settle it, and here is why nobody has produced that evidence yet" rather than "I read about this and it turns out oxytocin is fake."

That posture is the whole difference between skepticism and cynicism, and you need it constantly in Part III, where the disagreements are less honest and the stakes are more commercial.